<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="798">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096483</url>
  </required_header>
  <id_info>
    <org_study_id>104-2016-PTHS-0005</org_study_id>
    <nct_id>NCT03096483</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System</brief_title>
  <official_title>Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to collect survey data on the use of the OEC Elite Mobile
      Fluoroscopy System based on the routine clinical use of the device.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>imaging Guidance Adequacy assessed by Questionnaire</measure>
    <time_frame>Through Study Completion, expected completion in 2 months</time_frame>
    <description>Per-subject investigator report of imaging guidance adequacy to complete the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Investigator Procedure Surveys assessed by Survey Questionnaire</measure>
    <time_frame>Through Study Completion, expected completion in 2 months</time_frame>
    <description>The total number of surveys reflecting the investigator opinion of procedures performed and the image data collected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Interventional Vascular Conditions</condition>
  <arm_group>
    <arm_group_label>OEC Elite Imaging Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OEC Elite system</intervention_name>
    <description>Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures</description>
    <arm_group_label>OEC Elite Imaging Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female between the ages of 18 and 75 years (≥18 and ≤75 years old);

          2. Clinical indication for a vascular, gastrointestinal (GI), urology or pain management
             procedure for which mobile fluoroscopy has been prescribed;

          3. Able and willing to comply with study procedures; and

          4. Able and willing to provide written informed consent to participate.

        Exclusion Criteria:

          1. Pregnant or suspected to be pregnant based on the opinion of and as documented by a
             medically qualified physician investigator;

          2. Expected to be at increased risk due to study participation (e.g. due to allergies,
             sensitivities), in the medical opinion of an investigator; or

          3. Previously participated in this study, or enrolled in another active GEHC study or
             other research study that could be expected to interfere with participation in study
             procedures, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Beth Heckel</last_name>
    <phone>262-312-7269</phone>
    <email>beth.heckel@ge.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
